Cellectis Offers Enterprise Replace and Reviews 4th Quarter and Full Yr 2021 Monetary Outcomes

Cellectis Inc.

Cellectis Inc.

  • On monitor for deliberate 2022 IND submission for UCART20x22, our first allogeneic twin CAR T-cell product candidate, in B-cell non-Hodgkin’s Lymphoma

  • Two manufacturing websites at the moment are totally operational; on-track to dose sufferers with investigational medicinal merchandise manufactured in-house in 2022

  • Money place1 of $191 million as of December 31, 2021

  • Convention name scheduled for 8AM ET/2PM CET on March 4, 2022

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Progress: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology firm utilizing its pioneering gene-editing platform to develop doubtlessly life-saving cell and gene therapies, introduced its

Read More Read More